Her2-positive Lung Cancer Treated With Dedicated Drug
Condition(s):Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III; HER2 Gene MutationLast Updated:December 19, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III; HER2 Gene MutationLast Updated:December 19, 2023Completed
Condition(s):Non-Small Cell Lung Cancer (NSCLC)Last Updated:December 5, 2023Active, not recruiting
Condition(s):Non-small Cell Lung Cancer MetastaticLast Updated:August 7, 2017Unknown status
Condition(s):Non-Small Cell Lung CancerLast Updated:January 15, 2013Unknown status
Condition(s):Carcinoma; Non-Squamous Non-Small-Cell Lung CancerLast Updated:April 12, 2022Completed
Condition(s):Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC)Last Updated:March 27, 2024Recruiting
Condition(s):Metastatic Cancer; Soft Tissue Sarcoma; Merkel Cell Carcinoma; Melanoma; Triple Negative Breast Cancer; Non Small Cell Lung CancerLast Updated:February 26, 2024Recruiting
Condition(s):Metastatic Castration-resistant Prostate Cancer and Other Solid TumorsLast Updated:June 13, 2023Terminated
Condition(s):Carcinoma, Non-Small-Cell LungLast Updated:November 30, 2023Completed
Condition(s):Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid TumorsLast Updated:October 13, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.